Previous 10 | Next 10 |
Call Start: 08:30 Call End: 09:24 BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2022 Earnings Conference Call May 5, 2022 08:30 AM ET Company Participants John Bluth - SVP, IR and Corporate Communications Jon Stonehouse - Chief Executive Officer Anthony Doyle - Chief Financial Officer Dr. Bill She...
The following slide deck was published by BioCryst Pharmaceuticals, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: BioCryst Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation
BioCryst Pharmaceuticals (NASDAQ:BCRX) is trading ~9% lower in the pre-market Thursday after the commercial-stage biotech fell short of expectations with its 1Q 2022 financials and said that the FDA placed a partial clinical hold on studies involving oral factor D inhibitor BCX9930....
BioCryst Pharmaceuticals press release (NASDAQ:BCRX): Q1 GAAP EPS of -$0.40 misses by $0.03. Revenue of $49.92M (+161.9% Y/Y) misses by $1.44M. "The company had previously expected operating expenses for full year 2022, not including non-cash stock compensation, to be between $440 million to ...
—Q1 2022 ORLADEYO net revenue of $49.7 million— —ORLADEYO net revenue in 2022 expected to be no less than $250 million— —Company provides update on BCX9930 investigation— RESEARCH TRIANGLE PARK, N.C., May 05, 20...
BioCryst Pharmaceuticals (NASDAQ:BCRX) is scheduled to announce Q1 earnings results on Thursday, May 5th, before market open. The consensus EPS Estimate is -$0.40 (-11.1% Y/Y) and the consensus Revenue Estimate is $51.36M (+169.5% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward...
AAWW,ABEV,ABUS,ACIW,ADNT,ADT,AGIO,ALDX,ALE,AMCX,AMR,APD,APO,APTV,ARGX,ARW,AUTL,AVEO,BALY,BCE,BCRX,OTCQX:BDRBF,BDX,BERY,BFLY,BLD,BLL,OTC:BLRDF,BUD,BXRX,CAH,CARS,CBRE,CCJ,CCOI,CCRD,CIM,CIO,CMRE,CNCE,CNSL,COMM,COP,CROX,CTHR,CWEN,D,DBRG,DDOG,DEN,DFIN,OTCQX:DLAKF,DLX,DNOW,DTM,OTCQX:EDVMF,ENG,EPAM,...
American biotech BioCryst Pharmaceuticals (NASDAQ: BCRX) scored an important regulatory win across the Atlantic Ocean on Wednesday. As a result, happy shareholders pushed the company's stock almost 5% higher on the day. BioCryst announced that the European Medicines Agency (...
The European Medicines Agency (EMA) granted Priority Medicines (PRIME) designation to BioCryst Pharmaceuticals' (NASDAQ:BCRX) BCX9250 to treat fibrodysplasia ossificans progressiva (FOP). FOP is rare genetic disorder characterized by irregular formation f bone in areas where b...
RESEARCH TRIANGLE PARK, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the European Medicines Agency (EMA) has granted access to the Priority Medicines (PRIME) scheme for BCX9250, a novel, oral activin receptor-like kinase-2 (...
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for t...
2024-06-27 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-07 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...